FabiFlu Tablet contains favipiravir, an oral, broad-spectrum antiviral prodrug originally approved in Japan for influenza and later adapted for the treatment of mild to moderate COVID-19 in adults. In June 2020, Glenmark introduced FabiFlu to the Indian market making it the country's first approved oral antiviral option for managing the SARS-CoV-2 viral load.
Favipiravir belongs to a class of antiviral medicines that works by interfering with viral RNA-dependent RNA polymerase, an enzyme the virus needs to copy its genetic material. By disrupting this process, the medicine can limit the virus's ability to replicate inside the body.
FabiFlu is a prescription medicine and should be used only under medical supervision. The appropriate dose and treatment duration depend on the doctor's instructions and the patient's condition. The tablets should be taken as directed and should not be crushed, broken, or chewed unless specifically advised by a healthcare professional.
